JP2020516258A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516258A5
JP2020516258A5 JP2019555112A JP2019555112A JP2020516258A5 JP 2020516258 A5 JP2020516258 A5 JP 2020516258A5 JP 2019555112 A JP2019555112 A JP 2019555112A JP 2019555112 A JP2019555112 A JP 2019555112A JP 2020516258 A5 JP2020516258 A5 JP 2020516258A5
Authority
JP
Japan
Prior art keywords
compound
target
cells
iii
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019555112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516258A (ja
JP7319194B2 (ja
Filing date
Publication date
Priority claimed from EP17165784.4A external-priority patent/EP3388517A1/en
Priority claimed from EP17203591.7A external-priority patent/EP3489357A1/en
Application filed filed Critical
Priority claimed from PCT/EP2018/059173 external-priority patent/WO2018189186A1/en
Publication of JP2020516258A publication Critical patent/JP2020516258A/ja
Publication of JP2020516258A5 publication Critical patent/JP2020516258A5/ja
Priority to JP2023052030A priority Critical patent/JP7795493B2/ja
Application granted granted Critical
Publication of JP7319194B2 publication Critical patent/JP7319194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019555112A 2017-04-10 2018-04-10 ゲノム編集効率を増大させるための化合物 Active JP7319194B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023052030A JP7795493B2 (ja) 2017-04-10 2023-03-28 ゲノム編集効率を増大させるための化合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17165784.4A EP3388517A1 (en) 2017-04-10 2017-04-10 Compounds for increasing genome editing efficiency
EP17165784.4 2017-04-10
EP17203591.7 2017-11-24
EP17203591.7A EP3489357A1 (en) 2017-11-24 2017-11-24 Compounds for increasing genome editing efficiency
PCT/EP2018/059173 WO2018189186A1 (en) 2017-04-10 2018-04-10 Compounds for increasing genome editing efficiency

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023052030A Division JP7795493B2 (ja) 2017-04-10 2023-03-28 ゲノム編集効率を増大させるための化合物

Publications (3)

Publication Number Publication Date
JP2020516258A JP2020516258A (ja) 2020-06-11
JP2020516258A5 true JP2020516258A5 (https=) 2021-05-20
JP7319194B2 JP7319194B2 (ja) 2023-08-01

Family

ID=62116381

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019555112A Active JP7319194B2 (ja) 2017-04-10 2018-04-10 ゲノム編集効率を増大させるための化合物
JP2023052030A Active JP7795493B2 (ja) 2017-04-10 2023-03-28 ゲノム編集効率を増大させるための化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023052030A Active JP7795493B2 (ja) 2017-04-10 2023-03-28 ゲノム編集効率を増大させるための化合物

Country Status (9)

Country Link
US (1) US12173309B2 (https=)
EP (1) EP3610008A1 (https=)
JP (2) JP7319194B2 (https=)
KR (2) KR102537447B1 (https=)
CN (1) CN110691848B (https=)
CA (1) CA3058697A1 (https=)
IL (1) IL269887B2 (https=)
SG (1) SG11201909432SA (https=)
WO (1) WO2018189186A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200299729A1 (en) * 2017-09-08 2020-09-24 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
JP7235153B2 (ja) * 2017-12-29 2023-03-08 株式会社三洋物産 遊技機
JP7483612B2 (ja) 2018-01-17 2024-05-15 バーテックス ファーマシューティカルズ インコーポレイテッド ゲノム編集効率を増加するためのキノキサリノン化合物、組成物、方法、およびキット
CA3088788A1 (en) * 2018-01-17 2019-07-25 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
JP7235154B2 (ja) * 2018-02-15 2023-03-08 株式会社三洋物産 遊技機
JP7231076B2 (ja) * 2018-03-08 2023-03-01 株式会社三洋物産 遊技機
WO2020127738A1 (en) 2018-12-21 2020-06-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Dna-pkcs inhibitors for increasing genome editing efficiency
JP2020103418A (ja) * 2018-12-26 2020-07-09 株式会社三洋物産 遊技機
JP2020130466A (ja) * 2019-02-15 2020-08-31 株式会社三洋物産 遊技機
JP7234740B2 (ja) * 2019-03-28 2023-03-08 株式会社三洋物産 遊技機
JP7234741B2 (ja) * 2019-03-28 2023-03-08 株式会社三洋物産 遊技機
JP7234761B2 (ja) * 2019-04-11 2023-03-08 株式会社三洋物産 遊技機
JP7234760B2 (ja) * 2019-04-11 2023-03-08 株式会社三洋物産 遊技機
JP2021186294A (ja) * 2020-05-29 2021-12-13 株式会社三洋物産 遊技機
CN112359065B (zh) * 2020-09-21 2023-04-07 中国医学科学院血液病医院(中国医学科学院血液学研究所) 一种提高基因敲入效率的小分子组合物
KR102545913B1 (ko) * 2021-02-02 2023-06-22 재단법인 아산사회복지재단 히스톤 탈아세틸화 억제제를 포함하는 염기교정 기술의 효율성 및 정확도 향상용 조성물 및 이의 용도
EP4347815A2 (en) * 2021-05-24 2024-04-10 New York Genome Center, Inc. Compositions and methods for increasing efficiency of precise editing repair
CN113403309B (zh) * 2021-05-24 2022-08-16 珠海舒桐医疗科技有限公司 非同源双链寡聚核苷酸片段在基因敲除系统中的应用
EP4095246A1 (en) 2021-05-27 2022-11-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel crispr grnas
US20230070047A1 (en) * 2021-07-06 2023-03-09 Regents Of The University Of Minnesota Method to enhance gene editing
JP2023105111A (ja) * 2021-10-27 2023-07-28 株式会社三洋物産 遊技機
JP2023105108A (ja) * 2021-10-27 2023-07-28 株式会社三洋物産 遊技機
JP2023105110A (ja) * 2021-10-27 2023-07-28 株式会社三洋物産 遊技機
JP2023063369A (ja) * 2022-01-07 2023-05-09 株式会社三洋物産 遊技機
JP2023053387A (ja) * 2022-02-04 2023-04-12 株式会社三洋物産 遊技機
JP2023060269A (ja) * 2022-04-01 2023-04-27 株式会社三洋物産 遊技機
JP2023060270A (ja) * 2022-04-01 2023-04-27 株式会社三洋物産 遊技機
CN114717207B (zh) * 2022-04-25 2023-03-07 苏州泓迅生物科技股份有限公司 一种酵母细胞同源重组酶系、dna体外组装试剂及其应用
WO2025212548A1 (en) 2024-04-02 2025-10-09 Sigma-Aldrich Co. Llc Methods and compositions for improvement of base editor and homology directed repair genome editing outcomes
WO2026005012A1 (ja) * 2024-06-28 2026-01-02 学校法人自治医科大学 インビトロ及びインビボのゲノム編集における相同組換えの効率を高める方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188881A1 (en) 2012-06-15 2013-12-19 President And Fellows Of Harvard College Compounds, compositions and methods for treating or preventing neurodegenerative disorders
US10227610B2 (en) * 2013-02-25 2019-03-12 Sangamo Therapeutics, Inc. Methods and compositions for enhancing nuclease-mediated gene disruption
MX2015017312A (es) * 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
ES2730378T3 (es) * 2014-08-27 2019-11-11 Caribou Biosciences Inc Procedimientos para incrementar la eficiencia de la modificación mediada por Cas9
CA2963820A1 (en) * 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing

Similar Documents

Publication Publication Date Title
JP2020516258A5 (https=)
Ferrari et al. Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking
Brezgin et al. Dead Cas systems: types, principles, and applications
Mito et al. Protocol for disome profiling to survey ribosome collision in humans and zebrafish
He et al. The CRISPR/cas system: a customizable toolbox for molecular detection
Iyer et al. Efficient homology-directed repair with circular single-stranded DNA donors
Higuchi et al. Generation of pluripotent stem cells without the use of genetic material
JP7155021B2 (ja) 単細胞全ゲノムライブラリおよびそれを作成する組み合わせインデックス付加方法
Montalbano et al. High-throughput approaches to pinpoint function within the noncoding genome
Jiang et al. Robust strand exchange reactions for the sequence-specific, real-time detection of nucleic acid amplicons
Hilton et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers
Johne et al. Rolling-circle amplification of viral DNA genomes using phi29 polymerase
Patchsung et al. A multiplexed Cas13-based assay with point-of-care attributes for simultaneous COVID-19 diagnosis and variant surveillance
Fernandez et al. Optimized CRISPR-Cpf1 system for genome editing in zebrafish
Zhao et al. Alternative lengthening of telomeres (ALT) in tumors and pluripotent stem cells
Wilson et al. Engineered DNA ligases with improved activities in vitro
Li et al. Advances in the application of CRISPR-Cas technology in rapid detection of pathogen nucleic acid
Wu et al. Improving FnCas12a genome editing by exonuclease fusion
Skvarova Kramarzova et al. CRISPR/Cas9-mediated correction of the FANCD1 gene in primary patient cells
Moir-Meyer et al. Robust CRISPR/Cas9 genome editing of the HUDEP-2 erythroid precursor line using plasmids and single-stranded oligonucleotide donors
Kaulich et al. Combining CRISPR/Cas9 and rAAV templates for efficient gene editing
Zhou et al. Eliminating predictable DNA off-target effects of cytosine base editor by using dual guiders including sgRNA and TALE
Kohabir et al. In vitro CRISPR-Cas12a-based detection of cancer-associated TP53 hotspot mutations beyond the crRNA seed region
Sansbury et al. CRISPR-directed in vitro gene editing of plasmid DNA catalyzed by Cpf1 (Cas12a) nuclease and a mammalian cell-free extract
Rajamani et al. Genetic and epigenetic instability of stem cells